Autologous transfusion in acetabuloplasty in children

Area of Science:

• Pediatric Orthopedic Surgery
• Transfusion Medicine
• Biomedical Engineering

Background:

• Cerebral palsy (CP) often requires surgical intervention, such as acetabuloplasty for hip dysplasia.
• Blood transfusions are common in these procedures, carrying risks and costs associated with homologous blood.
• Autologous blood recovery systems offer a potential solution to minimize homologous blood use.

Purpose of the Study:

• To evaluate the efficacy and safety of a pediatric cell saver system in reducing homologous blood transfusions during acetabuloplasty in pediatric CP patients.
• To compare the volume of autologous and homologous blood transfused between the cell saver group and a control group.

Main Methods:

• A prospective study involving 22 pediatric patients (aged 6-17 years) with CP undergoing acetabuloplasty.
• Eleven patients received intraoperative autologous blood reinfusion using a pediatric cell saver.
• A control group of 11 patients received only banked homologous blood transfusions.

Main Results:

• The cell saver group received an average of 432 ml of autologous blood, significantly less homologous blood (2 units) compared to the control group (909 ml, 20 units).
• Autologous blood constituted 19.6% of total blood volume in the cell saver group versus 47% homologous blood in the control group.
• Homologous blood transfusion was avoided in 82% of patients utilizing the pediatric cell saver, with no reported complications.

Conclusions:

• Pediatric cell saver technology is effective in reducing homologous blood transfusion requirements in children with cerebral palsy undergoing hip surgery.
• The use of cell saver is a safe and viable alternative to homologous blood transfusion in this patient population.
• This approach minimizes exposure to banked blood and associated risks, improving patient outcomes.